Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery
Public ClinicalTrials.gov record NCT00254384. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Neoadjuvant Chemotherapy With Docetaxel, Cisplatin Followed by Maintenance Therapy With the EGFR Inhibitor Erlotinib (Tarceva) in Patients With Stage I, II and III Non-Small Cell Lung Cancer Following Definitive Surgical Resection
Study identification
- NCT ID
- NCT00254384
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 50 participants
Conditions and interventions
Conditions
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IA Lung Non-Small Cell Carcinoma AJCC v7
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7
- Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
- Stage IIB Lung Non-Small Cell Carcinoma AJCC v7
- Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
- Cisplatin Drug
- Docetaxel Drug
- Erlotinib Drug
- Erlotinib Hydrochloride Drug
- Laboratory Biomarker Analysis Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 4, 2005
- Primary completion
- May 20, 2024
- Completion
- May 20, 2024
- Last update posted
- Jul 4, 2024
2005 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00254384, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 4, 2024 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00254384 live on ClinicalTrials.gov.